# A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

Source: https://onco.cc/trials/nct04586231/  
OnCo record `nct04586231` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Belzutifan, Lenvatinib and Cabozantinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.

## Summary

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011) is a phase 3 interventional study registered as NCT04586231 by Merck Sharp & Dohme LLC, with 747 participants enrolled, started 2021-02-25 and due to reach its primary completion in 2026-02-02. Interventions recorded: Belzutifan, Lenvatinib and Cabozantinib.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04586231
- Phase: 3
- Setting: An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination With Lenvatinib (MK-7902) vs Cabozantinib in Participants With Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti-PD-1/L1 Therapy
- Sponsor: Merck Sharp & Dohme LLC
- Enrolled: 747

## Sources

- ClinicalTrials.gov NCT04586231: https://clinicaltrials.gov/study/NCT04586231

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- drugs: [Belzutifan](https://onco.cc/drugs/belzutifan/), [Cabozantinib](https://onco.cc/drugs/cabozantinib/), [Lenvatinib](https://onco.cc/drugs/lenvatinib/)
- companies: [Eisai](https://onco.cc/companies/eisai/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct04586231.json